2023
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer
Bergerot C, Philip E, Malhotra J, Bergerot P, Castro D, Govindarajan A, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi‐Raffle A, Tripathi A, Dorff T, Pal S. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer. Journal Of Genetic Counseling 2023, 33: 911-915. PMID: 37697864, DOI: 10.1002/jgc4.1786.Peer-Reviewed Original ResearchGenomic profilingKidney cancerEthnic differencesType of treatmentChi-square testGermline testingAdvanced prostateConsecutive patientsMost patientsWhite patientsMean ageSomatic testingPatients' perceptionsTreatment responsePatient decisionPatientsCancerSignificant differencesDNA sequencingProstateDescriptive statisticsEthnic groupsDifferencesProfiling
2022
Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Salgia S, Meza L, Zengin Z, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 327-327. DOI: 10.1200/jco.2022.40.6_suppl.327.Peer-Reviewed Original ResearchPhysician indicationGenitourinary cancersTreatment responseCommon reasonAdvanced genitourinary cancersMetastatic genitourinary cancerGenomic profiling testsCross-sectional studyEffective provider communicationChart reviewOlder patientsPatient characteristicsYounger patientsClinicopathologic characteristicsPatients' perceptionsProvider communicationPatient responsePatientsOlder ageGenomic profilingLow levelsCancerImportant associationProfiling testsGPsNivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Malhotra J, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment. Journal Of Clinical Oncology 2022, 40: 371-371. DOI: 10.1200/jco.2022.40.6_suppl.371.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaNivolumab/ipilimumabRenal cell carcinomaClinical outcomesIpilimumab armCell carcinomaTissue next-generation sequencingPhase Ib studyProtocol-based therapyHigh-risk diseaseGut microbial compositionGut microbiome functionalityGut microbiome functionPrior nephrectomyObjective responseSarcomatoid featuresMedian ageRisk diseaseWeek 12Body of evidenceIpilimumabStool samplesClear cellsTreatment responseIb study